Key Highlights

  • Total Revenue was USD 305.0 million, up 23.1%.
  • Operating income was USD 13.9 million, down 36.3%.
  • Medical Solutions revenue rose 30.3%; Automation Enabling Technologies rose 16.0%.
  • Riverpoint Medical closed July 23 for USD 1,200.6 million.

Novanta Inc. (NASDAQ:NOVT) reported total revenue of USD 305.0 million for the three months ended October 2, 2026, an increase of USD 57.2 million, or 23.1%, from the prior year period. Reported EPS was USD 1.05 and revenue was USD 305.01 million, compared with estimates of EPS of USD 0.97 and revenue of USD 301.02 million.

The company attributed the increase primarily to revenue from the 2026 acquisition, a 16.0% increase in Automation Enabling Technologies and a 3.5% increase in Medical Solutions excluding the acquisition. The Acquisition added USD 32.9 million, or 13.3%, while foreign currency exchange rates had an unfavorable USD 0.3 million effect.

Segment Performance

Automation Enabling Technologies revenue increased USD 20.0 million, or 16.0%, primarily on a 17.3% increase in robotics and automation products and a 13.7% increase in precision Manufacturing products, tied to end market Demand and new product introductions. Segment Gross Profit increased USD 13.7 million, or 23.1%, on higher revenue and gross profit margin.

Medical Solutions revenue increased USD 37.1 million, or 30.3%, primarily due to USD 32.9 million of revenue contributions from the 2026 acquisition.

For the nine months ended October 2, 2026, the medical market accounted for approximately 52% of revenue and the advanced industrial market approximately 48%.

Earnings and Costs

Operating income was USD 13.9 million, a decrease of USD 7.9 million, or 36.3%. The company attributed this to a USD 16.4 million increase in restructuring, acquisition and related costs, a USD 7.8 million increase in amortization expense, a USD 6.2 million increase in selling, general and administrative expenses and a USD 2.3 million increase in Research and Development and engineering expenses, partially offset by a USD 24.7 million increase in gross profit.

Net income was USD 2.0 million, compared with USD 10.7 million. Diluted EPS under GAAP was USD 0.05, a decrease of USD 0.25, which the company tied primarily to lower Net Income and an increase in weighted average common shares outstanding.

Total revenue for the nine months was USD 828.5 million, an increase of USD 106.3 million, or 14.7%, primarily from the 2026 and 2025 acquisitions, an 11.5% increase in Automation Enabling Technologies and a 6.2% increase in Medical Solutions excluding acquisitions. Acquisitions contributed USD 41.9 million, or 5.8%, and foreign currency had a favorable USD 10.3 million, or 1.4%, effect.

Operating income was USD 59.5 million, a decrease of USD 9.7 million, or 14.0%. Net income was USD 35.7 million, compared with USD 36.4 million, and diluted EPS was USD 0.86, a decrease of USD 0.15.

Acquisition and Financing

On July 23, 2026, the company completed the acquisition of all outstanding Equity interests of the Parent Company of Riverpoint Medical for total upfront cash consideration of USD 1,200.6 million, net of cash acquired, subject to customary closing and net Working Capital adjustments. It funded the purchase with USD 616.0 million of borrowings under the revolving Credit Facility and delayed draw term Loan facility of its credit agreement, with the remainder from cash on hand.

A Placement that closed on June 11, 2026 generated net proceeds of approximately USD 288.0 million, recorded as an increase to additional paid-in capital.

Segments, Riverpoint and Costs

Novanta's revenue of USD 305.0 million includes the Riverpoint Medical acquisition, which closed July 23 for USD 1,200.6 million. The filing details the acquisition contribution, the market split of revenue and the cost items behind the 36.3% decline in Operating Income to USD 13.9 million.